Chemotherapy for gliomas in mainland China: An overview

Sai,Ke; Yang,Qun-Ying; Shen,Dong; Chen,Zhong-Ping

doi:10.3892/ol.2013.1264

Chemotherapy for gliomas in mainland China: An overview

Authors:
- Ke Sai
- Qun-Ying Yang
- Dong Shen
- Zhong-Ping Chen
View Affiliations

Affiliations: Department of Neurosurgery/Neuro-Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou 510060, P.R. China
Published online on: March 19, 2013 https://doi.org/10.3892/ol.2013.1264
Pages: 1448-1452

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapy is currently the standard treatment modality for malignant gliomas. Many patients with gliomas are treated in mainland China every year. The history and development of chemotherapy for glioma, however, are not well documented. In this study, an extensive literature search of Pubmed and major Chinese electronic databases was performed to identify clinical studies. A total of 210 publications were identified, with a total of 10,105 patients. Among these studies, 76.2% were retrospective and 23.8% were prospective. Chemotherapy was found to have been administered by the Department of Neurosurgery in 143 studies (68.1%). Oral or intravenous administration was found in 55.7% of studies, followed by intra-arterial (26.7%) and interstitial (15.7%) chemotherapy. Nitrosoureas were the most frequently used chemotherapeutic agents, as found in 133 studies (63.3%). Since 2003, 56 studies on temozolomide (TMZ) have been published. Studies on chemotherapy for gliomas began in the 1970s in mainland China but well-designed randomized controlled trials (RCTs) are rare. Much effort and collaboration should be made to carry out high-quality multicenter RCTs on chemotherapy for gliomas.

View Figures

View References

1	Schwartzbaum JA, Fisher JL, Aldape KD and Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2:494–503; quiz 1 p following 516. 2006. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
3	Minniti G, Muni R, Lanzetta G, Marchetti P and Enrici RM: Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 29:5171–5184. 2009.PubMed/NCBI
4	Cairncross G, Macdonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials. Group J Clin Oncol. 12:2013–2021. 1994.PubMed/NCBI
5	Yung WK, Prados MD, Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor. Group J Clin Oncol. 17:2762–2771. 1999.PubMed/NCBI
6	Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.
7	Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 359:1011–1018. 2002. View Article : Google Scholar : PubMed/NCBI
8	Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
9	Hart MG, Grant R, Garside R, Rogers G, Somerville M and Stein K: Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev CD. 0072942011.PubMed/NCBI
10	Friedman HS, Prados MD, Wen PY, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009. View Article : Google Scholar : PubMed/NCBI
11	Tianjin Medical School Affliated Hospital: Preliminary study on BCNU in the treatment of intracranial tumors: report of 45 cases. Tianjin Med J. 15:26–28. 1973.(In Chinese).
12	The First Affliated Hospital to Suzhou Medical School: Preliminary observation of treating gliomas in central nervous system with CCNU. Chin J Nerv Ment Dis. 1:51–53. 1975.(In Chinese).
13	Zeng X and Yang S: Clinical observation in chemotherapy with temozolomide alone in postoperative malignant primary cerebral glioma. Mod J Neurol Neurosurg. 3:270–273. 2003.
14	Newton HB: Intra-arterial chemotherapy of primary brain tumors. Curr Treat Options Oncol. 6:519–530. 2005. View Article : Google Scholar : PubMed/NCBI
15	Tyler JL, Yamamoto YL, Diksic M, et al: Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET. J Nucl Med. 27:775–780. 1986.PubMed/NCBI
16	Shapiro WR, Green SB, Burger PC, et al: A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg. 76:772–781. 1992. View Article : Google Scholar : PubMed/NCBI
17	Westphal M, Hilt DC, Bortey E, et al: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 5:79–88. 2003.PubMed/NCBI
18	Lin Y, Chen W, Zhuge Q, et al: Combined CT-guided stereo-tactic interstitial radiotherapy of 32P and MTX chemotherapy for treatment of deep brain gliomas. Chin J Neurosurg. 12:216–218. 1996.(In Chinese).
19	Qi S and Qiu B: Treatment of recurrent malignant brain gliomas by surgical excision combined with biodegradable polymers of interstitial chemotherapy. Zhonghua Zhong Liu Za Zhi. 26:58–61. 2004.(In Chinese).
20	Li A, Zhang X, Yi Y, et al: Interstitial chemotherapy for malignant chemotherapy. Chin J Clin Neurosurg. 4:24–26. 1999.(In Chinese).
21	Buckner JC: Factors influencing survival in high-grade gliomas. Semin Oncol. 30:10–14. 2003. View Article : Google Scholar
22	Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 60:166–193. 2010.PubMed/NCBI